0
0
GENEVA – In a move that will define the next chapter of global pharmaceutical access, the World Health Organization (WHO) officially opened the application window today, May 1, 2026, for the 2027 update of its Model Lists of Essential Medicines (EML).
The announcement sets the stage for the 26th meeting of the WHO Expert Committee, scheduled for May 2027. This biennial tradition is more than just a bureaucratic milestone; it is the primary mechanism through which the world’s leading health authority determines which treatments are “essential” for every human being, regardless of their country’s wealth or development level.
With the deadline for submissions set for November 6, 2026, researchers, pharmaceutical companies, and health advocates now have six months to build the evidence-based cases that could bring new, life-saving therapies to billions of people.
Why the EML Matters to You
For the average consumer, the EML may sound like a high-level policy document, but its impact is felt at the pharmacy counter. Since its inception in 1977, the list has grown from 205 items to over 520 medicines in the most recent 2025 update.
When a medicine is added to the WHO EML:
-
National Policy Changes: Over 150 countries use the WHO list to create their own national medicine lists, which dictate what drugs the government will buy and which ones insurance plans will cover.
-
Lower Costs: Inclusion often signals to generic manufacturers that there is a high, steady demand, which can trigger competition and lower prices.
-
Guaranteed Quality: It sets a global standard for what a “basic” healthcare system must provide, from simple antibiotics to advanced cancer immunotherapies.
The Road to 2027: A Rigorous Evidence-Based Journey
The selection process is notoriously stringent. Unlike typical regulatory approvals that focus solely on “Does it work?”, the WHO Expert Committee evaluates medicines based on a complex matrix of public health relevance, safety, effectiveness, and comparative cost-effectiveness.
The Criteria for Essentiality
To be considered for the 2027 list, an application must demonstrate:
-
Public Health Relevance: Does the medicine treat a disease that affects a large number of people or poses a significant threat?
-
Clinical Evidence: Is there robust data (often from Phase III trials) proving it is safer or more effective than what is already available?
-
Feasibility: Can it be used safely in diverse environments, including rural clinics with limited refrigeration or specialized staff?
“The EML is a key tool for achieving universal health coverage,” the WHO stated in its departmental update. “It guides governments and procurers on which medicines offer the best value in terms of benefits for individuals and communities.”
Lessons from 2025
The upcoming 2027 cycle will likely build on the groundbreaking shifts seen in the 2025 update. Last year, the committee made waves by adding GLP-1 agonists (like semaglutide) for specific diabetes complications and expanding the list of cancer immunotherapies. However, they also famously rejected several applications, including methylphenidate for ADHD, citing a need for more long-term safety data.
This underscores a core principle of the committee: inclusion is not guaranteed by innovation alone; it requires proof of long-term benefit for the public good.
Expert Perspectives: Balancing Innovation and Access
While the medical community largely views the EML as the “gold standard” for public health, the process is not without its critics. Independent health policy experts often point to the “implementation gap”—the distance between a drug being on a list in Geneva and being available in a remote village.
“The challenge for the 2027 committee will be addressing the high cost of new ‘essential’ biologics,” says Dr. Elena Rossi, a global health policy consultant (not affiliated with the WHO). “We are seeing a trend where highly effective but incredibly expensive drugs for cancer and rare diseases are being added. While this is a win for science, it puts immense pressure on the budgets of low-income countries.”
Rossi notes that the committee has increasingly used the EML as a “negotiating tool,” signaling to the world that these drugs should be affordable, even if they currently are not.
How to Apply: A Call to Stakeholders
The WHO has streamlined the process for the 2027 cycle, emphasizing transparency. Applicants—ranging from NGOs and medical associations to private companies—are “strongly encouraged” to contact the EML Secretariat early.
Key Deadlines & Links:
-
Application Deadline: November 6, 2026, 18:00 UTC.
-
Submission Format: PDF and Word formats via email to
[email protected]. -
Expert Committee Meeting: May 3–7, 2027, in Geneva.
Prospective applicants must follow the updated “Instructions for Applicants” guide, which requires a detailed summary of the clinical evidence and an analysis of the “budget impact” for health systems.
The Public Health Outlook
As we look toward 2027, the medical world anticipates applications for more advanced antimicrobial treatments to combat rising drug resistance, as well as new vaccines for emerging viral threats.
For the patient waiting for a better treatment, the opening of this application period is the first step toward that medicine becoming a standard of care worldwide. It is a reminder that in global health, the pen of the Expert Committee can be as powerful as the scientist’s microscope.
Reference Section
Primary Source:
-
World Health Organization (WHO). “Application period now open for the 2027 update of the WHO Model Lists of Essential Medicines.” Published May 1, 2026. [URL: https://www.who.int/news/item/01-05-2026-application-period-now-open-for-the-2027-update-of-the-who-model-lists-of-essential-medicines]
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
